Suppression of Glioma progression by Egln3

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Sciorra, Vicki A ^a   Sanchez, Michael A ^a   Kunibe, Akemi ^a   Wurmser, Andrew E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; HYPOXIA INDUCIBLE FACTOR; KRUPPEL LIKE FACTOR 5; OXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN EGLN3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CAPILLARY; CARCINOGENESIS; CELL ASSAY; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; TUMOR VASCULARIZATION;

ANIMALS; BRAIN NEOPLASMS; DIOXYGENASES; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMEDIATE-EARLY PROTEINS; KINETICS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OCTAMER TRANSCRIPTION FACTOR-3; RATS; TREATMENT OUTCOME;

RODENTIA;

EID: 84864710505     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040053     Document Type: Article

References (52)

1. Du R, Lu KV, Petritsch C, Liu P, Ganss R, et al. (2008) HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13: 206-220.
2. Li Z, Bao S, Wu Q, Wang H, Eyler C, et al. (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501-513.
3. Rong Y, Durden DL, Van Meir EG, Brat DJ, (2006) 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65: 529-539.
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
5. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF, (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14: 43-47.
6. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, et al. (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622.
7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
8. Keith B, Simon MC, (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129: 465-472.
9. Rankin EB, Rha J, Unger TL, Wu CH, Shutt HP, et al. (2008) Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 27: 5354-5358.
10. Ryan HE, Lo J, Johnson RS, (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. Embo J 17: 3005-3015.
11. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr, (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246.
12. Liao D, Corle C, Seagroves TN, Johnson RS, (2007) Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67: 563-572.
13. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, et al. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 94: 8104-8109.
14. Semenza GL, (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8: S62-67.
15. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, et al. (2004) Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6: 485-495.
16. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, et al. (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88: 2606-2618.
17. Semenza GL, (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
18. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, et al. (2006) HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570.
19. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN, (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8: 3274-3284.
20. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
21. Du Z, Jia D, Liu S, Wang F, Li G, et al. (2009) Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia 57: 724-733.
22. Holmberg J, He X, Peredo I, Orrego A, Hesselager G, et al. (2011) Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human glioma. PLoS One 6: e18454.
23. Kaelin WG Jr, (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
24. Semenza GL, (2003) Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 54: 17-28.
25. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, et al. (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279: 38458-38465.
26. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, et al. (2009) Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15: 527-538.
27. Chan DA, Giaccia AJ, (2010) PHD2 in tumour angiogenesis. Br J Cancer 103: 1-5.
28. Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, et al. (2003) Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res 63: 8777-8783.
29. Hatzimichael E, Dasoula A, Shah R, Syed N, Papoudou-Bai A, et al. (2010) The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. Eur J Haematol 84: 47-51.
30. Henze AT, Riedel J, Diem T, Wenner J, Flamme I, et al. (2010) Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res 70: 357-366.
31. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, et al. (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136: 839-851.
32. Xue J, Li X, Jiao S, Wei Y, Wu G, et al. (2010) Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology 138: 606-615.
33. Garcia JA, (2009) Aiming straight for the heart: prolyl hydroxylases set the BAR. Sci Signal 2: pe70.
34. Zhang Q, Gu J, Li L, Liu J, Luo B, et al. (2009) Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 16: 413-424.
35. Parisi S, Passaro F, Aloia L, Manabe I, Nagai R, et al. (2008) Klf5 is involved in self-renewal of mouse embryonic stem cells. J Cell Sci 121: 2629-2634.
36. Shindo T, Manabe I, Fukushima Y, Tobe K, Aizawa K, et al. (2002) Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 8: 856-863.
37. Yan Q, Bartz S, Mao M, Li L, Kaelin WG Jr, (2007) The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol 27: 2092-2102.
38. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr, (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1: E83.
39. Jain RK, (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
40. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A, (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579.
41. Plate KH, Breier G, Weich HA, Risau W, (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848.
42. Wurmser AE, Nakashima K, Summers RG, Toni N, D'Amour KA, et al. (2004) Cell fusion-independent differentiation of neural stem cells to the endothelial lineage. Nature 430: 350-356.
43. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, et al. (2005) Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155-167.
44. Bordoli MR, Stiehl DP, Borsig L, Kristiansen G, Hausladen S, et al. (2011) Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis. Oncogene 30: 548-560.
45. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
46. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563.
47. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, et al. (2008) Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453: 410-414.
48. Kashiwagi S, Tsukada K, Xu L, Miyazaki J, Kozin SV, et al. (2008) Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 14: 255-257.
49. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, et al. (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6: 14.
50. Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, et al. (2008) Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 265: 124-134.
51. Lai K, Kaspar BK, Gage FH, Schaffer DV, (2003) Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci 6: 21-27.
52. Ray J, Gage FH, (2006) Differential properties of adult rat and mouse brain-derived neural stem/progenitor cells. Mol Cell Neurosci 31: 560-573.